<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430534</url>
  </required_header>
  <id_info>
    <org_study_id>HN/P001-EBV-003</org_study_id>
    <nct_id>NCT00430534</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals’ EBV (Epstein Barr Virus) Vaccine (268664).</brief_title>
  <official_title>To Evaluate the Safety, Immunogenicity and Efficacy of GSK Biologicals’ EBV Vaccine (268664) in Healthy Seronegative Adolescents/Adults When Injected Intramuscularly According to a 0-1-5 Month Schedule in Belgium.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henogen</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, immune-response and efficacy of GSK Biologicals’ EBV vaccine in a
      population at risk of developing infectious mononucleosis. Each subject will receive three
      doses of vaccine or placebo during the study period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attack rates of infectious mononucleosis over 18 months after Dose 2</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited symptoms (Day 0-7); unsolicited AEs (Day 0-29 ); SAEs (full study)</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Epstein Barr Virus (EBV) Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EBV vaccine (268664)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adolescent/adult subjects between and including 16 and 25 years of age at the
             time of screening.

               -  Written informed consent obtained from the subject prior to enrolment.

               -  Seronegative for EBV antibody.

        Exclusion Criteria:

          -  Administration of immunoglobulin and/or any blood products within the three months (90
             days) preceding the first dose of study vaccine or planned administration during the
             study period.

               -  Use of any investigational or non-registered drug or vaccine other than the study
                  vaccine within 30 days preceding the first dose of study vaccine, or planned use
                  during the study period.

               -  Any confirmed or suspected immunosuppressive or immunodeficient condition,
                  including human immunodeficiency virus (HIV) infection.

               -  Family history of congenital or hereditary immunodeficiency.

               -  Major congenital defects or serious chronic illness.

               -  History of any neurologic disorders or seizures, with the exception of a single
                  febrile seizure during childhood.

               -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or
                  renal functional abnormality, as determined by physical examination or laboratory
                  screening tests.

               -  History of intravenous drug abuse within the past 2 years.

               -  Known or suspected allergy to any vaccine component.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Henogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>February 1, 2007</last_update_submitted>
  <last_update_submitted_qc>February 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2007</last_update_posted>
  <keyword>Epstein Barr Virus</keyword>
  <keyword>Belgium</keyword>
  <keyword>Infectious mononucleosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

